Acute Coronary Care in the Elderly, Part I
Authors:
- L. Kristin NewbyLNL. Kristin Newby
- Christopher P. CannonCCChristopher P. Cannon
- Paul W. ArmstrongPAPaul W. Armstrong
- W. Brian GiblerWGW. Brian Gibler
- Michael W. RichMRMichael W. Rich
- Frans Van de WerfFWFrans Van de Werf
- Harvey D. WhiteHWHarvey D. White
- W. Douglas WeaverWWW. Douglas Weaver
- Mary D. NaylorMNMary D. Naylor
- Joel M. GoreJGJoel M. Gore
- Harlan M. KrumholzHKHarlan M. Krumholz
Top Cited Papers
- 15 May 2007
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 115 (19) , 2549-2569
Abstract
Background— Age is an important determinant of outcomes for patients with acute coronary syndromes (ACS); however, community practice reveals a disproportionately lower use of cardiovascular medications and invasive treatment even among elderly patients with ACS who would stand to benefit. Reasons include limited trial data to guide the care of older adults and uncertainty about benefits and risks, particularly with newer medications or invasive treatments and in the setting of advanced age or complex health status. Methods and Results— This 2-part American Heart Association scientific statement summarizes evidence on patient heterogeneity, clinical presentation, and treatment of non–ST-elevation ACS in relation to age ( Conclusions— Although a few recent trials have described treatment effects in older patients, others continue to exclude patients on the basis of age. Going forward, prospective trials should enroll elderly subjects proportionate to their prevalence among the treated population to define risk and benefit. Findings from age subgroup analyses should be reported in a consistent manner across trials, including absolute and relative risks for efficacy and safety. Outcomes of particular relevance to the elderly, such as quality of life, physical function, and independence, should also be considered. Creatinine clearance should be calculated for every elderly patient to enable appropriate dosing. In addition, physicians need an understanding of conditions unique to older patients (eg, frailty, cognitive impairment) that influence treatment goals and outcomes. With these efforts, treatment risks can be minimized, and benefits can be placed in the health context of the elderly patient with ACS.Keywords
This publication has 102 references indexed in Scilit:
- Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial)The American Journal of Cardiology, 2005
- Influence of clinical trial enrollment on the quality of care and outcomes for patients with non–ST-segment elevation acute coronary syndromesAmerican Heart Journal, 2005
- Impact of age on management and outcome of acute coronary syndrome: Observations from the global registry of acute coronary events (GRACE)American Heart Journal, 2005
- A Validated Prediction Model for All Forms of Acute Coronary SyndromeJAMA, 2004
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993
- Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the antithrombotic therapy in acute coronary syndromes study group)The American Journal of Cardiology, 1990
- Aspirin, Heparin, or Both to Treat Acute Unstable AnginaNew England Journal of Medicine, 1988
- Incidence and Prognosis of Unrecognized Myocardial InfarctionNew England Journal of Medicine, 1984
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976